Compounds > mk 386

Page last updated: 2024-11-11

mk 386

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4,7beta-dimethyl-4-azacholestan-3-one: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9888107
SCHEMBL ID	916924
MeSH ID	M0239552

Synonyms (18)

Synonym
mk 386
mk-386
jwdkp12euc ,
2h-indeno(5,4-f)quinolin-2-one, 7-((1r)-1,5-dimethylhexyl)hexadecahydro-1,4a,6a,10-tetramethyl-, (4ar,4bs,6ar,7r,9as,9bs,10s,11ar)-
158493-17-5
unii-jwdkp12euc
4-azacholestan-3-one, 4,7-dimethyl-, (5alpha,7beta)-
2h-indeno(5,4-f)quinolin-2-one, 7-(1,5-dimethylhexyl)hexadecahydro-1,4a,6a,10-tetramethyl-, (4ar-(4aalpha,4bbeta,6aalpha,7alpha(r*),9abeta,9balpha,10alpha,11abeta))-
4,7beta-dimethyl-4-azacholestan-3-one
SCHEMBL916924
(4ar,4bs,6ar,7r,9as,9bs,10s,11ar)-7-[(1r)-1,5-dimethylhexyl]hexadecahydro-1,4a,6a,10-tetramethyl-2h-indeno[5,4-f]quinolin-2-one
2h-indeno(5,4-f)quinolin-2-one, 7-(1,5-dimethylhexyl)hexadecahydro-1,4a,6a,10-tetramethyl-, (4ar-(4a.alpha.,4b.beta.,6a.alpha.,7.alpha.(r*),9a.beta.,9b.alpha.,10.alpha.,11a.beta.))-
4-azacholestan-3-one, 4,7-dimethyl-, (5.alpha.,7.beta.)-
AKOS032947167
DTXSID20935926
(1r,3as,3bs,4s,5ar,9ar,9bs,11ar)-4,6,9a,11a-tetramethyl-1-[(2r)-6-methylheptan-2-yl]-2,3,3a,3b,4,5,5a,8,9,9b,10,11-dodecahydro-1h-indeno[5,4-f]quinolin-7-one
HY-106951
CS-0026984

Research Excerpts

Compound-Compound Interactions

Excerpt	Reference	Relevance
" Small increases in serum T were observed with finasteride alone and in combination with MK-386 (approximately 10% and 19%, respectively)."	( Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men. Chavez, CM; Constanzer, ML; De Lepeleire, I; De Schepper, PJ; Ebel, DL; Gertz, BJ; Justice, SJ; Lasseter, KC; Schwartz, JI; Shamblen, EC; Van Hecken, A; Wang, DZ; Winchell, GA, 1996)	0.29

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	7 (50.00)	18.2507
2000's	6 (42.86)	29.6817
2010's	1 (7.14)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	27.09 (24.57)
Research Supply Index	2.83 (2.92)
Research Growth Index	4.31 (4.65)
Search Engine Demand Index	24.28 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (27.09)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (14.29%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	2.05	1	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
corticosterone [no description available]	2	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	2.4	2	0	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
pregnenolone [no description available]	1.99	1	0	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	4.34	2	2	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
boldenone boldenone: RN given refers to (17beta)-isomer. boldenone : An 3-oxo-Delta(1),Delta(4)-steroid substituted by an oxo group at position 3 and a beta-hydroxy group at position 17. It is an anabolic androgenic steroid that has been developed for veterinary use.	2	1	0	17beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; anabolic androgenic steroid
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	1.99	1	0	benzenes; phenyl acetates
androstane-3,17-diol Androstane-3,17-diol: The unspecified form of the steroid, normally a major metabolite of TESTOSTERONE with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.	3.38	1	1	17-hydroxy steroid; 3-hydroxy steroid; androstanoid
atamestane atamestane: aromatase inhibitor; structure given in first source	2	1	0
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	5.75	11	2	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
androstane-3,17-diol glucuronide androstane-3,17-diol glucuronide: RN given refers to cpd with unspecified glucuronide locant	3.38	1	1	steroid ester
11-dehydrocorticosterone 11-dehydrocorticosterone : An 11-oxo steroid that is corticosterone in which the hydroxy substituent at the 11beta position has been oxidised to give the corresponding ketone.	2	1	0	11-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; corticosteroid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	2.04	1	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor

Condition	Indicated	Relationship Strength	Studies	Trials
Cancer of Prostate [description not available]	0	2.73	3	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	2.73	3	0
Adenoma, Prostatic [description not available]	0	2.02	1	0
Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.	0	2.02	1	0
Hepatocellular Carcinoma [description not available]	0	1.99	1	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	0	1.99	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	1.99	1	0
Aura [description not available]	0	2	1	0
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	0	2	1	0